Understanding and Diagnosing Allergic Disease in Twins The purpose of this study is to gain better understanding of how the immune system works in
twins with and without allergic disease. Healthy volunteers are not specifically targeted.
Healthy non-allergic study participants may be found through the course of evaluation for the
presence of allergies.Kari Nadeau, MD, PhDLearn More »
Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy The objectives of this dose-finding study for the treatment of peanut allergy are:
- To determine the efficacy of 3 doses of Viaskin Peanut (50 mcg ,100 mcg and 250 mcg
peanut protein per patch) to significantly desensitize peanut-allergic subjects to
peanut after 12 months of treatment.
- To evaluate the safety of a long-term treatment …Kari Nadeau, MD, PhDLearn More »
Safety Study of Viaskin Peanut to Treat Peanut Allergy This study evaluates the safety of Viaskin Peanut 250 mcg in the treatment of peanut allergy
in children from 4 to 11 years of age. Subjects will receive either Viaskin Peanut 250 mcg or
a placebo for a period of 6 months, after which all subjects will be receiving the active
treatment up to a period of 3 years under active treatment.R. Sharon ChinthrajahLearn More »
Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center The long-term goal of the investigators study is to develop a better and safer treatment for,
and to potentially cure patients with single or multiple food allergies. The investigators
hypothesize that the application of this protocol will allow patients with severe and single
or multiple food allergies to be safely and rapidly desensitized.Learn More »
Xolair Treatment for Milk Allergic Children This is a pilot feasibility study, using Xolair pretreatment for oral milk desensitization.
The major assessment will be safety, and the investigators will evaluate for any type of
reaction, including allergic reactions that occur during the course of the study.Learn More »
Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial The investigators will perform a double blind, placebo controlled clinical trial with Xolair
(omalizumab) at four centers to safely and rapidly desensitize patients with severe peanut
allergy. The investigators will determine if pretreatment with anti-IgE mAb
(Xolair/omalizumab) can greatly reduce allergic reactions and allow for faster and safer
desensit…Learn More »
